Table 1.
EV treatments in transplantation-related settings.
| Author | Model | EV origin | Qtyc | EV infusion (d = days) | ISd | Conclusion |
|---|---|---|---|---|---|---|
| Pêche et al. (112) | Rat heterotopic heart TXa | imDexb | 10 μg | d14 pre-TX d7 pre-TX | None | Short term survival, donor-specific |
| Pêche et al. (97) | Rat heterotopic heart TX | imDex | 25 μg | d1 post-TX d6 post-TX | LF15-0195 | Long term survival, donor-specific, transferable |
| Yang et al. (122) | Rat intestinal TX | imDex | 20 μg | d7 pre-TX | None | Short term survival |
| Li et al. (123) | Mouse heterotopic heart TX | imDex | 10 μg | d7 pre-TX, d0, d7 post-TX | Rapamycin | Short term survival, donor-specific, transferable |
| Kordelas et al. (109) | Human refractory GvHD | MSC-EVs | 1 Unit | Several doses | Steroids | Reduced clinical GvHD |
aTX, transplant.
bimDex, immature dendritic cell-derived EVs.
cQty, quantity of EVs administered.
dIS, immunossuppressive drug regime.